An Italian Study: Paclitaxel Plus Epirubicin in Advanced Breast Cancer

ONCOLOGY

Volumn 12, Issue 1 SUPPL.1, 1998, Pages 40-44

  Conte, Pier Franco ^a   Gennari, Alessandra ^a   Salvadori, Barbara ^a   Pazzagli, Ilaria ^a   Bengala, Carmelo ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; COLONY STIMULATING FACTOR RECEPTOR; EPIRUBICIN; EPIRUBICINOL; PACLITAXEL;

ADULT; ADVANCED CANCER; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; HUMAN; LEUKAPHERESIS; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; WORLD HEALTH ORGANIZATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; EPIRUBICIN; FEMALE; HUMANS; PACLITAXEL;

EID: 0031939936     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Seidman AD: The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1:247-256, 1996.
2. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
3. Abrams JC, Vena DH, Boltz J, et al: Paclitaxel activity in heavily pre-treated breast cancer: A National Cancer Institute Treatment Referral Center Trial. J Clin Oncol 13:2056-2065, 1995.
4. Conte PF, Gennari A: Anthracyclines/paclitaxel combinations in the treatment of breast cancer. Ann Oncol 8:339-343, 1997.
5. Sledge GW Jr, Robert M, Sparano JA, et al: Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 21(suppl 8):15-18, 1994.
6. Fisherman JS, Cowan KH, Noone K, et al: Phase I-II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte-stimulating-factor in patients with metastatic breast cancer J Clin Oncol 14:774-782, 1996
7. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
8. 8a. Gehl J, Boesgaard M, Paaske T, et al: Combined doxorubicin and paclitaxel in advanced breast cancer. Effective and cardiotoxic. Ann Oncol 7:687-693, 1996.
9. 8b. Gianni L, Capri G, Tarenzi E, et al: Efficacy and cardiac effects of 3-h paclitaxel plus bolus doxorubicin in women with untreated metastatic breast cancer (abstract 128). Proc Am Soc Clin Oncol 15:116, 1996.
10. 8c. Moliterni A, Tarenzi E, Capri G, et al. Pilot study of primary CT with doxorubicin plus pach taxel in women with locally advanced breast cancer or operable breast cancer. Semin Oncol 24(suppl 17):10-14, 1997
11. Conte PF, Michelotti A, et al: A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer. Semin Oncol 5 28-31, 1996.
12. Bonadonna G, Gianni L, Santoro A, et al Drugs ten years later: Epirubicin. Ann Oncol 4 359-369, 1993.
13. Gennari A, Salvadori B, Tognoni A, et al: Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann Oncol 7:978, 1996.
14. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment Cancer 47:207-214, 1981
15. Conte PF, Baldini E, Gennari A, et al: Dose finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours. A regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 19:2510-2517, 1997.
16. Jamis-Dow CA, Klecker R, Sarosy G, et al: Steady-state plasma concentration and effects of Taxol at a 250 mg/m2 dose in combination with granulocyte colony-stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33.48-52, 1993.
17. Jakobsen P, Sorensen B, et al: The pharmacokinetics of high dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil and tamoxifen in metastatic breast cancer patients Cancer Chemother Pharmacol 35:45-52, 1994.
18. Bengala C, Pattagli I, Tibaldi C, et al: Mobilization, collection and characterization of peripheral blood progenitors after epirubicin plus paclitaxel and granulocyte-colony stimulating factor (G-CSF) in patients with metastatic breast cancer. Cancer, 1996 (in press).
19. Focan C, Andrien JM, Closan MT, et al: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial J Clin Oncol 11: 1253-1263, 1993.
20. Marschner N, Kreienberg R, Souchon R, et al. Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: Interim analysis of a prospective randomized trial. Semin Oncol 21(suppl 1):10-16, 1994
21. Bastholt L, Dalmark M, Gjedde SB, et al: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different levels performed by Danish Breast Cancer Cooperative Group. J Clin Oncol 14: 1146-1155, 1996
22. Nabholtz JM, Gelman K, Bontenbal, et al: Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
23. Plosker GL, Faulds D: Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cancer chemotherapy. Drugs 45:788-856, 1993.
24. Berg SL, Cowan KH, Balis FM, et al: Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 86:143-145, 1994.
25. Holmes FA, Madden T, Newman RA, et al: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14:2713-2721, 1996.
26. Gianni L, Kearns CM, Gianni A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995.
27. Olson RD, Mushlin PS: Doxorubicin cardiotoxicity analysis of prevailing hypothesis. FASEB J 4.3076-3086, 1990.
28. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy in metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995.
29. Catimel G, Spielmann M, Dieras V, et al: Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: A preliminary report on safety. Semin Oncol 23(suppl 1):24-27, 1996.
30. Luck HJ, Thomsenn C, duBois A, et al: Interim analysis of a phase II study of epirubicin and paclitaxel as first line therapy in patients with metastatic breast cancer. Semin Oncol 23(suppl 1):33-36, 1996.